Cytosorbents Corp. | Ownership

Companies that own Cytosorbents Corp.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
BlackRock Fund Advisors
1,583,535
5.03%
1,452,839
0%
06/30/2018
The Vanguard Group, Inc.
1,200,326
3.82%
206,777
0%
06/30/2018
Skylands Capital LLC
496,550
1.58%
-190,400
0.89%
06/30/2018
SSgA Funds Management, Inc.
434,632
1.38%
413,053
0%
06/30/2018
Northern Trust Investments, Inc.
309,268
0.98%
261,154
0%
06/30/2018
Manatuck Hill Partners LLC
258,200
0.82%
12,000
1.33%
06/30/2018
Allianz Global Investors U.S. LLC
257,670
0.82%
257,670
0.01%
06/30/2018
Geode Capital Management LLC
239,199
0.76%
94,317
0%
06/30/2018
Renaissance Technologies LLC
230,300
0.73%
230,300
0%
06/30/2018
Two Sigma Advisers LP
214,151
0.68%
214,151
0.01%
06/30/2018

About Cytosorbents

View Profile
Address
7 Deer Park Drive
Monmouth Junction New Jersey 08852
United States
Employees -
Website http://cytosorbents.com
Updated 07/08/2019
CytoSorbents Corp. engages in the development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product, CytoSorb, is a extracorporeal cytokine filter and seeks to reduce cytokine storm that could otherwise cause massive inflammation, organ failure, and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.